Biotech Just Had Its Big Reset - Here’s What Comes Next (Dan Rasmussen, D.A. Wallach & Meb Faber)

Key Concepts

• Biotech is a uniquely uncorrelated and highly dispersed sector, requiring modified factor models for effective investment.
• Traditional equity factor models (value, quality, momentum) are ineffective in biotech without adaptation.
• China is becoming a crucial player in biotech, driven by government investment, lower trial costs, and a growing talent pool.
• Recent corporate profit increases are largely attributed to US government deficits rather than productivity gains.
• Global wealth has increased fivefold in the past 60 years, primarily through asset price appreciation, not corporate investment.
• Japan presents an economic anomaly with high debt but no crisis, potentially due to government asset holdings and secular stagnation.
• Japanese corporate governance reforms are driving increased payouts to shareholders, creating potential investment opportunities.
• The US stock market dominates global equity markets, with higher participation rates than most other countries.
• Maintaining government deficits appears to have broad political and economic support, potentially sustaining equity market performance.

Biotech Sector Analysis & Investment Strategies (Parts 1 & 2)

The discussion began with the recent strong performance of biotech stocks (up 50% since July 4th) and a deep dive into Dan Rasmussen’s research on the sector. Rasmussen’s work demonstrates that traditional equity factor models fail in biotech due to its unique characteristics: high uncorrelation with other sectors and high internal dispersion.

To address this, he developed modified factor definitions. “Value” is redefined as Market Cap to Spend (excluding cash from Enterprise Value), recognizing that biotech companies prioritize spending over revenue generation. “Quality” is measured by “Specialist Holders” – the percentage of ownership by funds specializing in biotech, leveraging their in-house scientific expertise. “Momentum” is replaced with “Peer Momentum,” analyzing the performance of companies in similar clinical trials (using the Mesh Tree classification system).

Biotech represents 25% of US companies but a small portion of overall market capitalization due to the prevalence of small-cap companies. Returns follow a power law distribution: 70% of unprofitable companies lose money, 50% of losing companies are acquired at negative returns, 10% delist, and 40% become “zombie” companies. Fraud risk is a concern, mitigated by specialist fund due diligence.

The growing importance of China in biotech was highlighted, with the Chinese government investing heavily in R&D, increasing M&A activity (30-40% of acquisitions in 2025), offering lower clinical trial costs, and attracting returning Chinese scientists.

Macroeconomic Trends & Corporate Profitability (Part 2)

The conversation shifted to broader macroeconomic trends, arguing that recent corporate profit increases are primarily driven by US government deficits. Government spending boosts demand for US corporate products, and corporations have largely distributed profits through dividends and buybacks, benefiting wealthy shareholders who reinvest in equity markets. This cycle is described as a potentially unsustainable dynamic.

A 2020 McKinsey report revealed a five-fold increase in global net worth over the past 60 years, driven by price increases and multiple expansion rather than corporate investment. Continued deficit spending could sustain this trend, potentially leading to lower expected returns (higher CAPE ratio/lower ERP).

Japan: An Economic Outlier (Part 2)

Japan was presented as an economic anomaly, defying conventional theories by avoiding a debt crisis despite a deficit of 200% of GDP. The government’s substantial holdings of financial assets are a mitigating factor. Larry Summers’ “secular stagnation” hypothesis was introduced, suggesting low returns on investment incentivize insufficient investment and savings gluts. Faster productivity growth, driven by technology, is crucial.

Recent corporate governance reforms in Japan are driving increased payouts (dividends and buybacks). Japanese companies historically held significant assets on their balance sheets (seven years of net income vs. one year in the US), now potentially distributable to shareholders. Nominal GDP growth and increasing foreign investment are positive catalysts. Private equity opportunities exist, but cultural resistance to restructuring presents a barrier.

Global Market Dynamics & Future Outlook (Part 2)

The US stock market now represents approximately two-thirds of global market capitalization (up from 30% previously). Disparities in equity participation rates globally – high in the US, low in many other countries – may contribute to continued US market outperformance.

The discussion concluded that maintaining government deficits has broad support from both the poorest Americans (reliant on entitlements) and the wealthiest (benefiting from rising equity valuations), potentially sustaining equity market performance. The importance of identifying mispriced assets and long-term trends was reiterated.

Conclusion

The discussion synthesized insights from biotech investing and broader macroeconomic trends. It highlighted the need for specialized analytical approaches in unique sectors like biotech, while also questioning the sustainability of current corporate profit levels driven by government deficits. The analysis of Japan offered a contrasting perspective, demonstrating how unconventional economic policies can mitigate traditional debt-related risks. Ultimately, the conversation underscored the importance of understanding both micro-level investment opportunities and the underlying macroeconomic forces shaping global markets.